|
© 2004 American Academy of Neurology Brief Communications Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combinationFrom the Departments of Neurology (Drs. Lipton and Bigal), Epidemiology and Population Health (Dr. Lipton), Albert Einstein College of Medicine, Bronx, NY; The New England Center for Headache (Dr. Bigal), Stamford, CT; AdvancePCS (Drs. Kolodner and Wilks), Hunt Valley, MD; Department of Neurology (Dr. Gorelick), RUSH Medical College, Chicago, IL; and Boehringer Ingelheim (Drs. Schoebelock and Davidai), Ridgefield, CT. Address correspondence and reprint requests to Dr. Richard B. Lipton, Albert Einstein College of Medicine, Department of Neurology, 1300 Morris Park Avenue, Bronx, NY 10461; e-mail: Rlipton{at}aecom.yu.edu The authors assessed the prevalence of headaches following extended-release dipyridamole/aspirin combination (DAC), and the efficacy of acetaminophen in the treatment of these headaches. Following DAC, 38.7% of the participants developed headaches. The headaches were self-limited (69.4% placebo efficacy in 2 hours) and the incidence markedly declined over time. Acetaminophen was no more effective than placebo in the acute and preemptive treatment of these headaches.
Received December 4, 2003. Accepted in final form May 14, 2004. Dr. Gorelick has received honoraria in excess of $10,000 from Boehringer Ingelheim.
Related Article
This article has been cited by other articles:
|
||||||||||||